Adial Pharmaceuticals logo
Adial Pharmaceuticals ADIL

Annual report 2025
added 03-05-2026

report update icon

Adial Pharmaceuticals Net Debt 2011-2026 | ADIL

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Adial Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - -5.85 M -4.4 M -6.78 M -3.87 M 671 K 146 K -162 K - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
671 K -6.78 M -2.89 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Burford Capital Limited Burford Capital Limited
BUR
-135 M $ 4.73 0.42 % $ 761 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
-76.6 M $ 3.4 4.29 % $ 342 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
-604 M $ 333.39 -1.77 % $ 43.7 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-3.5 M $ 3.17 3.93 % $ 5.22 M israelIsrael
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-34.7 M $ 3.73 3.04 % $ 8.97 B australiaAustralia
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Aligos Therapeutics Aligos Therapeutics
ALGS
-132 M $ 7.42 -15.1 % $ 73.3 M usaUSA
Allakos Allakos
ALLK
-25 M - - $ 28.6 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Applied Therapeutics Applied Therapeutics
APLT
-49.4 M - - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
-49.6 M - -13.39 % $ 1.45 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
457 M $ 21.68 1.4 % $ 1.01 B usaUSA
BioNTech SE BioNTech SE
BNTX
-973 M $ 99.47 1.08 % $ 27.2 B germanyGermany
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
-133 M - - $ 399 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
-75.5 M $ 4.24 2.17 % $ 453 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
65.3 M $ 24.58 -2.03 % $ 3.13 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
533 K - -2.5 % $ 5.88 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-31.2 M - 1.93 % $ 17.4 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
-33.1 M - -4.8 % $ 255 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-32.7 M $ 1.49 0.68 % $ 397 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-3.56 B - 0.49 % $ 251 B cayman-islandsCayman-islands
AVROBIO AVROBIO
AVRO
-76.6 M - 1083.1 % $ 745 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
-13.6 M $ 2.75 4.16 % $ 1.22 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K - - $ 7.46 M israelIsrael
bluebird bio bluebird bio
BLUE
-163 M - - $ 546 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
9.86 B - - $ 96.9 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Cidara Therapeutics Cidara Therapeutics
CDTX
-188 M - - $ 1.41 B usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
-5.45 M - - $ 310 B britainBritain
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
-165 M $ 2.17 5.85 % $ 451 M usaUSA